Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies

Journal of Psychiatric Practice
Matthew MacalusoSheldon H Preskorn

Abstract

This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients treated with antipsychotics. The first column in this series began with the case of a 76-year-old man with major depressive disorder who developed orofacial dyskinesias while being treated with aripiprazole as an antidepressant augmentation strategy. It was alleged that a higher than intended dose of aripiprazole (ie, 20 mg/d for 2 wk followed by 10 mg/d for 4 wk instead of the intended dose of 2 mg/d) was the cause of the dyskinetic movements in this man, and the authors were asked to review the case and give their opinion. The principal basis for this theory of causation was the class warning about TD in the package insert for aripiprazole. The rationale for concluding aripiprazole caused TD in the 76-year-old man led to this series of columns about aripiprazole, its potential--if any--to cause TD, and the presence of a class warning about TD in its ...Continue Reading

References

Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Jul 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Fuji YokoiDean F Wong
May 17, 2005·European Journal of Pharmacology·Yoshihiro TadoriTetsuro Kikuchi
Jul 2, 2005·Journal of Psychiatric Practice·S H Preskorn
Aug 2, 2007·Journal of Psychiatric Practice·Sheldon H Preskorn
Aug 9, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nathalie GinovartShitij Kapur
Sep 23, 2010·Journal of Psychiatric Practice·Sheldon H Preskorn
May 19, 2011·Journal of Psychiatric Practice·Matthew MacalusoSheldon H Preskorn
Jun 23, 2011·Journal of Clinical Psychopharmacology·Hiroyuki UchidaDavid C Mamo
Jul 22, 2011·Journal of Psychiatric Practice·Matthew MacalusoSheldon H Preskorn
Sep 20, 2012·The Australian and New Zealand Journal of Psychiatry·Jacob Alexander, Samantha Bickerstaff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.